Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | HPN | P05981 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796158 | 0.83 | EGFR (0.45) | CYP2D6MAPK1ALDH1A1GAACA12 | |
| SCHEMBL4801052 | 0.82 | ALDH1A1 (0.42) | CYP2D6MAPK1ALDH1A1GAACA12 | |
| SCHEMBL4983476 | 0.82 | CYP2D6 (0.51) | CYP2D6MAPK1ALDH1A1GAACA12 | |
| SCHEMBL4473496 | 0.76 | NPY2R (0.36) | CYP2D6MAPK1GAACA12CA1 | |
| SCHEMBL13960640 | 0.76 | TP53 (0.36) | CYP2D6SCN2AALDH1A1GAACA12 | |
| SCHEMBL4798350 | 0.74 | KMT2A (0.44) | ALDH1A1GAACA12CA1CA2 | |
| SCHEMBL20550796 | 0.74 | ALDH1A1 (0.47) | MAPK1ALDH1A1GAALMNAHTT | |
| SCHEMBL7096179 | 0.74 | KMT2A (0.44) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL4464947 | 0.73 | CYP19A1 (0.34) | CYP2D6ALDH1A1GAACA12CA1 | |
| SCHEMBL30716686 | 0.73 | MEN1 (0.44) | ALDH1A1CA2LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476677-B2 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1716155-B1 | SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | ASTRA ZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| EP-1716155-A1 | SUBSTITUTED THIENO¬2,3-D|PYRIMIDINES AS INHIBITORS OF TIE2 | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005075483-A1 | SUBSTITUTED THIENO - AND THIAZOLO - [2, 3-D] PYRIDINES AS INHIBITORS OF TIE2 | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135455-A1 | Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 | TIE1, TEK, TEKT1 | CYP2D6 1776/4885MAPK1 678/4885SCN2A 3108/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | CYP2D6 579/4885MAPK1 2106/4885SCN2A 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.